Growing sales at Ipsen as Galderma collab falls apart

French drugmaker Ipsen (Euronext: IPN) has reported a 7.2% increase in revenues in the first half of 2023, driven in part by newly-acquired medicines Bylvay (odevixibat) and Tazverik (tazemetostat).

Total revenues came in at 1.5 billion euros ($1.65 billion), while net profits fell 6% to 393 million euros, yielding earnings per share (EPS) of 4.73 euros.

The company has also announced the termination of a collaboration with dermatology company Galderma,  inked in 2014, after the latter initiated arbitration proceedings via the International Chamber of Commerce.